2016
Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report
Merola J, Yoo PS, Schaub J, Smith JD, Rodriguez-Davalos MI, Tichy E, Mulligan DC, Asch W, Formica R, Kashgarian M, Kulkarni S. Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report. Transplantation Proceedings 2016, 48: 3106-3108. PMID: 27932157, DOI: 10.1016/j.transproceed.2016.04.005.Peer-Reviewed Original ResearchConceptsCalcineurin inhibitorsHemolytic uremic syndromeThrombotic microangiopathyKidney transplantationUremic syndromeMinimization of CNIsAtypical hemolytic uremic syndromeWithdrawal of tacrolimusEarly graft lossFavorable clinical courseGraft dysfunctionGraft lossImmunosuppression strategiesUsual therapyClinical courseCase reportCTLA-4Endothelial reactionFrequent causeChallenging causeUncontrolled activationMonoclonal antibodiesCellular destructionMicroangiopathyComponent C5De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemia
2014
Donor-Derived West Nile Virus Infection in Solid Organ Transplant Recipients
Winston DJ, Vikram HR, Rabe IB, Dhillon G, Mulligan D, Hong JC, Busuttil RW, Nowicki MJ, Mone T, Civen R, Tecle SA, Trivedi KK, Hocevar SN. Donor-Derived West Nile Virus Infection in Solid Organ Transplant Recipients. Transplantation 2014, 97: 881-889. PMID: 24827763, PMCID: PMC5765745, DOI: 10.1097/tp.0000000000000024.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsWest Nile virus infectionTransplant recipientsWNV infectionCerebrospinal fluidIntravenous immunoglobulinUnexplained feverWNV IgMVirus infectionRT-PCROrgan donorsWNV RNAReverse transcription polymerase chain reaction testingTranscription polymerase chain reaction testingSerological assaysPolymerase chain reaction testingReduction of immunosuppressionSymptomatic WNV infectionCommon clinical presentationOrgan transplant recipientsWNV activityFresh frozen plasmaPotential organ donorsConfirmation of infectionNeurologic deficits
2013
Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
2012
Polyomavirus JC Urinary Shedding in Kidney and Liver Transplant Recipients Associated With Reduced Creatinine Clearance
Kusne S, Vilchez RA, Zanwar P, Quiroz J, Mazur MJ, Heilman RL, Mulligan D, Butel JS. Polyomavirus JC Urinary Shedding in Kidney and Liver Transplant Recipients Associated With Reduced Creatinine Clearance. The Journal Of Infectious Diseases 2012, 206: 875-880. PMID: 22802433, PMCID: PMC3501156, DOI: 10.1093/infdis/jis469.Peer-Reviewed Original ResearchConceptsJohn Cunningham virusSolid organ transplant recipientsLiver transplant recipientsOrgan transplant recipientsTransplant recipientsBK virusTransplant patientsUrinary sheddingKidney recipientsCreatinine clearanceReduced creatinine clearanceKidney transplant patientsLiver transplant patientsOrgan transplant patientsPolyomavirus BK virusJCV loadLiver recipientsPolyomavirus reactivationRenal dysfunctionSignificant morbidityPatient groupCrCl valuesLiver patientsPatientsKidney
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1Resolution of Long-Standing Necrobiosis Lipoidica Diabeticorum (NLD) Lesion After Restoration of Euglycemia Following Successful Pancreas After Kidney (PAK) Transplantation: A Case Report
Mazur M, Lowney A, Prigoff J, Heilman R, Chakkera H, Moss A, Mulligan D, Reddy K, Hamawi K. Resolution of Long-Standing Necrobiosis Lipoidica Diabeticorum (NLD) Lesion After Restoration of Euglycemia Following Successful Pancreas After Kidney (PAK) Transplantation: A Case Report. Transplantation Proceedings 2011, 43: 3296-3298. PMID: 22099781, DOI: 10.1016/j.transproceed.2011.10.005.Peer-Reviewed Original ResearchConceptsNecrobiosis lipoidica diabeticorumKidney transplantationPancreas transplantationType I diabetic recipientsTight diabetic controlInflammatory skin disorderRestoration of euglycemiaSuccessful pancreasDiabetic controlDiabetes mellitusDiabetic recipientsImmunosuppressive agentsCase reportUnknown causeCase of resolutionConsistent efficacySkin disordersTransplantationEuglycemiaPatientsPancreasTreatmentImmunosuppressionMellitusRegimen
2010
Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin
Reddy K, Devarapalli Y, Mazur M, Hamawi K, Chakkera H, Moss A, Mekeel K, Post D, Heilman R, Mulligan D. Alemtuzumab with Rapid Steroid Taper in Simultaneous Kidney and Pancreas Transplantation: Comparison to Induction with Antithymocyte Globulin. Transplantation Proceedings 2010, 42: 2006-2008. PMID: 20692393, DOI: 10.1016/j.transproceed.2010.05.090.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdrenal Cortex HormonesAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumCreatinineDrug Therapy, CombinationGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney TransplantationMycophenolic AcidPancreas TransplantationPatient SelectionRetrospective StudiesConceptsRapid steroid taperAcute rejection episodesR-ATG groupR-ATGSimultaneous kidneySteroid taperBK nephropathyRejection episodesPancreas transplantationAlemtuzumab groupClinical acute rejection episodesRabbit antithymocyte globulin inductionAntithymocyte globulin inductionR-ATG inductionMean serum creatinineHistoric control groupPostoperative day 4Alemtuzumab inductionAntithymocyte globulinGlobulin inductionMaintenance immunosuppressionTransplant characteristicsGraft survivalCMV infectionCytomegalovirus infection
2009
Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Clinical Transplants 2009, 407-14. PMID: 20524306.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAgedAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmBoronic AcidsBortezomibCreatinineFemaleGraft RejectionHLA AntigensHumansImmunoglobulins, IntravenousImmunosuppressive AgentsIsoantibodiesKidney TransplantationMaleMiddle AgedProtease InhibitorsPyrazinesRituximabTreatment OutcomeOutcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match
Heilman R, Chakkera H, Mazur M, Petrides S, Moss A, Mekeel K, Mulligan D, Reddy K. Outcomes of Simultaneous Kidney–Pancreas Transplantation With Positive Cross-Match. Transplantation Proceedings 2009, 41: 303-306. PMID: 19249540, DOI: 10.1016/j.transproceed.2008.08.154.Peer-Reviewed Original ResearchMeSH KeywordsAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, NeoplasmAntilymphocyte SerumDrug Therapy, CombinationFollow-Up StudiesGraft SurvivalHistocompatibility TestingHumansImmunoglobulins, IntravenousImmunosuppressive AgentsKidney TransplantationPancreas TransplantationRetrospective StudiesSurvival AnalysisTime FactorsTreatment OutcomeConceptsAntibody-mediated rejectionLow-dose intravenous immunoglobulinAcute cellular rejectionIntravenous immunoglobulinStudy groupControl groupAllograft survivalMycophenolate mofetilRisk of AMRSimultaneous pancreas-kidney transplant recipientsPancreas-kidney transplant recipientsSimultaneous kidney-pancreas transplantationDose intravenous immunoglobulinKidney-pancreas transplantationPositive cross matchRabbit antithymocyte globulinActuarial patient survivalKidney allograft survivalKidney transplant recipientsPancreas allograft survivalAcute rejectionAntithymocyte globulinCellular rejectionSPKT recipientsKidney allografts
2007
Laparoscopic incisional hernia repair after liver transplantation
Mekeel K, Mulligan D, Reddy KS, Moss A, Harold K. Laparoscopic incisional hernia repair after liver transplantation. Liver Transplantation 2007, 13: 1576-1581. PMID: 17969189, DOI: 10.1002/lt.21290.Peer-Reviewed Original ResearchConceptsLaparoscopic incisional hernia repairIncisional hernia repairLAP groupLiver transplantationHernia repairOP groupMore patientsLaparoscopic ventral hernia repairTime of transplantationLength of stayVentral hernia repairNontransplant patientsPrimary immunosuppressionWound complicationsRecurrent ascitesLaparoscopic approachMesh removalOpen repairRetrospective reviewDecreased incidenceMesh infectionIncisional herniaLower riskPatientsTransplantation
2006
Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab
Heilman RL, Reddy KS, Mazur MJ, Moss AA, Post DJ, Petrides S, Mulligan DC. Acute Rejection Risk in Kidney Transplant Recipients on Steroid-Avoidance Immunosuppression Receiving Induction With Either Antithymocyte Globulin or Basiliximab. Transplantation Proceedings 2006, 38: 1307-1313. PMID: 16797289, DOI: 10.1016/j.transproceed.2006.02.116.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionSteroid avoidance immunosuppressionKidney transplant recipientsAntithymocyte globulinAcute rejectionTransplant recipientsMonths posttransplantationAcute rejection-free survivalType 1 diabetes mellitusRabbit antithymocyte globulinRejection-free survivalAcute rejection riskInduction therapyMaintenance immunosuppressionProtocol biopsiesRapid discontinuationMost patientsDiabetes mellitusMedian timeLower incidenceRejection riskBasiliximabImmunosuppressionDay 4Overall risk
2005
Immunosuppression in liver transplantation
Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transplantation 2005, 11: 1307-1314. PMID: 16237688, DOI: 10.1002/lt.20614.Peer-Reviewed Original ResearchSteroid Avoidance Immunosuppression in Low-Risk Kidney Transplant Recipients
Heilman R, Mazur M, Reddy K, Moss A, Post D, Mulligan D. Steroid Avoidance Immunosuppression in Low-Risk Kidney Transplant Recipients. Transplantation Proceedings 2005, 37: 1785-1788. PMID: 15919466, DOI: 10.1016/j.transproceed.2005.02.106.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsLow-risk kidney transplant recipientsChronic allograft nephropathyPostoperative day 3Steroid avoidanceTransplant recipientsLow-immunologic risk kidney transplant recipientsDay 3Anti-thymocyte globulin inductionRabbit anti-thymocyte globulinRisk kidney transplant recipientsIncidence of PTDMPositive flow crossmatchSteroid avoidance immunosuppressionTrough tacrolimus levelsAnti-thymocyte globulinGraft survival ratesSerum creatinine levelsShort-term safetyRecent clinical trialsDay of transplantationActuarial patientAcute rejectionAllograft nephropathyGlobulin induction
2004
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response
2003
Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation
St. Peter SD, Post DJ, Rodriguez‐Davalos M, Douglas DD, Moss AA, Mulligan DC. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transplantation 2003, 9: 144-149. PMID: 12548508, DOI: 10.1053/jlts.2003.50018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBilirubinDouble-Blind MethodFemaleHumansImmunosuppressive AgentsLiver TransplantationMaleMiddle AgedProthrombin TimeReperfusion InjurySolutionsTacrolimusConceptsIschemia/reperfusion injuryTacrolimus treatmentReperfusion injuryFlush solutionGroup 2Group 1Partial thromboplastin time valuesBaseline aspartate aminotransferaseEarly graft functionOrthotopic liver transplantProspective randomized fashionTotal ischemia timeSerum laboratory valuesSuperior early graft functionGraft functionLiver transplantLiver transplantationHepatic allograftsHepatocellular injuryLiver injuryPlacebo treatmentLiver diseasePlasma-Lyte AHepatocellular damageIschemia timeEffects of tacrolimus on ischemia‐reperfusion injury
St. Peter SD, Moss AA, Mulligan DC. Effects of tacrolimus on ischemia‐reperfusion injury. Liver Transplantation 2003, 9: 105-116. PMID: 12548502, DOI: 10.1053/jlts.2003.50020.Peer-Reviewed Original ResearchConceptsEffects of tacrolimusIschemia-reperfusion injuryCellular mechanismsCalcium-activated pathwaysInteractions of tacrolimusFree radical metabolismCornerstone agentEfficacious immunosuppressionInflammatory cascadeOrgan transplantationTacrolimusCytoprotective effectsTissue recoveryClinical literatureDiverse actionsRadical metabolismImmunosuppressionInjuryMitochondrial stabilityStress response proteinsReperfusionIschemiaTransplantationTranscription factorsMicrocirculation
1997
Influence of steroid withdrawal on proteinuria in renal allograft recipients.
Ghandour FZ, Knauss TC, Mulligan DC, Schulak JA, Hricik DE. Influence of steroid withdrawal on proteinuria in renal allograft recipients. Clinical Transplantation 1997, 11: 395-8. PMID: 9361929.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnalysis of VarianceAnti-Inflammatory AgentsAzathioprineChi-Square DistributionChronic DiseaseCreatinineCyclosporineFemaleFollow-Up StudiesGlucocorticoidsGraft RejectionHumansImmunosuppressive AgentsKidney TransplantationLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrednisoneProteinuriaRecurrenceTransplantation, HomologousConceptsSteroid withdrawalUrinary protein excretionAllograft rejectionProtein excretionPrimary renal transplant recipientsAcute allograft rejectionRenal allograft recipientsRenal transplant recipientsChronic allograft rejectionSpot urine specimensAcute rejectionAllograft recipientsSteroid therapyTransplant recipientsClinical variablesUrine creatinineUrine specimensPatientsProteinuriaWithdrawalExcretionRecipientsRejectionCreatinineTransplantationReduction of early rejection in adult liver transplantation with ATG induction therapy
Schulak J, May E, Post A, Fasola C, Mulligan D, Sterling R. Reduction of early rejection in adult liver transplantation with ATG induction therapy. Transplantation Proceedings 1997, 29: 555-556. PMID: 9123126, DOI: 10.1016/s0041-1345(96)00264-3.Peer-Reviewed Original Research
1995
Monitoring of allograft recipients for the development of HLA-specific antibodies: elimination of OKT3 as a complicating factor.
Mulligan D, Gentry L, Dombrausky L, Klintmalm G, Nikaein A. Monitoring of allograft recipients for the development of HLA-specific antibodies: elimination of OKT3 as a complicating factor. Clinical Transplantation 1995, 9: 438-41. PMID: 8645885.Peer-Reviewed Original ResearchConceptsOKT3 MoAbPatient seraPanel reactive antibody (PRA) assayPositive reactivityAnti-HLA antibodiesHLA-specific antibodiesOKT3 monoclonal antibodyFalse-positive reactivityMismanagement of patientsAllograft recipientsHumoral rejectionTransplant recipientsAntibody assaysRabbit antimouse immunoglobulinAntibody developmentMonoclonal antibodiesMoAbSerumAntibodiesAntimouse immunoglobulinRecipientsComplicating factorsOKT3PatientsImmunoglobulin